Free Trial Information
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...a target of $100 million.DBV gains as path clears for peanut allergy programDBV Technologies S.A. (Euronext:DBV...
...develop “theranostics.” Financial terms were not disclosed. BC Staff Viaskin Peanut (DBV-712) Ultomiris, ravulizumab-cwvz (ALXN1210) Darzalex Faspro, DARA-PH20, subcutaneous daratumumab DBV Technologies S.A. Thermo...
Read More
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...By Danielle Golovin, Staff Writer Food allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) announced that Hugh Sampson is stepping down from...
...effective Dec. 1. Sampson will remain as scientific adviser to the CEO and chairman of DBV’s...
...formerly EVP for research and development at H. Lundbeck A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera...
Read More
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...the therapy significantly improved remission rates vs. placebo.EMA reviewing DBV’s peanut allergy patch Shares of DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) rose...
...on NASDAQ Monday after the company said EMA is reviewing its MAA for Viaskin Peanut (DBV-712...
...with Ig and ITIM domainsXPO1 (CRM1) – Nuclear export (SINE) protein exportin 1 Danielle Golovin Viaskin Peanut (DBV-712) Jyseleca...
Read More
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...chief commercial officer. He was VP of business planning and operations in North America for DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Sandi...
Read More
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...a complete response letter this month for a rival therapy, Viaskin Peanut epicutaneous patch from DBV Technologies S.A....
Read More
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...Jordan as its first chief commercial officer. He was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV...
Read More
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...pediatric patients, and, by mid-2021, seek EMA approval. Setback for DBV’s peanut allergy therapy DBV Technologies S.A. (Euronext:DBV...
...citing concerns regarding the impact of patch-site adhesion on efficacy; and requested additional CMC data. DBV...
...Staff Viaskin Peanut (DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point...
Read More
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...DBV expects delay for peanut allergy product DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date...
...scheduled for May 15 to discuss the BLA and may require an additional data submission, DBV...
...HuLuc63, BMS-901608, PDL 063) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Xerava, eravacycline (TP-434, IV TP-434) teplizumab (MGA031, PRV-031) Viaskin Peanut (DBV-712) Novo...
Read More
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

...the food allergy therapeutic pipeline," Dombkowski said. Two companies with competing peanut allergy therapies, DBV Technologies S.A. (Euronext:DBV...
...$1 billion around their treatments. Aimmune's Palforzia peanut allergen powder has gained FDA approval, while DBV's...
Read More
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...Geller as head of intellectual property. She held the same role at Casebia Therapeutics. DBV Technologies S.A. (Euronext:DBV...
...development at Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara Inc. Pharvaris B.V. DBV Technologies S.A. Complexa...
Read More
Items per page:
1 - 10 of 146
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

...a target of $100 million.DBV gains as path clears for peanut allergy programDBV Technologies S.A. (Euronext:DBV...
...develop “theranostics.” Financial terms were not disclosed. BC Staff Viaskin Peanut (DBV-712) Ultomiris, ravulizumab-cwvz (ALXN1210) Darzalex Faspro, DARA-PH20, subcutaneous daratumumab DBV Technologies S.A. Thermo...
Read More
BioCentury | Nov 25, 2020
Management Tracks

DBV CSO stepping down; plus moves at Idera, Ultimovacs, Omniome, Humacyte and Aelis Farma

...By Danielle Golovin, Staff Writer Food allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) announced that Hugh Sampson is stepping down from...
...effective Dec. 1. Sampson will remain as scientific adviser to the CEO and chairman of DBV’s...
...formerly EVP for research and development at H. Lundbeck A/S (CSE:LUN) before retiring in 2018. Danielle Golovin DBV Technologies S.A. Idera...
Read More
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...the therapy significantly improved remission rates vs. placebo.EMA reviewing DBV’s peanut allergy patch Shares of DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) rose...
...on NASDAQ Monday after the company said EMA is reviewing its MAA for Viaskin Peanut (DBV-712...
...with Ig and ITIM domainsXPO1 (CRM1) – Nuclear export (SINE) protein exportin 1 Danielle Golovin Viaskin Peanut (DBV-712) Jyseleca...
Read More
BioCentury | Sep 3, 2020
Management Tracks

Dier joining Ultragenyx as CFO; plus Magenta, Galectin, Immunicum, BrainStorm, Vaccinex

...chief commercial officer. He was VP of business planning and operations in North America for DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Sandi...
Read More
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

...a complete response letter this month for a rival therapy, Viaskin Peanut epicutaneous patch from DBV Technologies S.A....
Read More
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...Jordan as its first chief commercial officer. He was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV...
Read More
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...pediatric patients, and, by mid-2021, seek EMA approval. Setback for DBV’s peanut allergy therapy DBV Technologies S.A. (Euronext:DBV...
...citing concerns regarding the impact of patch-site adhesion on efficacy; and requested additional CMC data. DBV...
...Staff Viaskin Peanut (DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point...
Read More
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...DBV expects delay for peanut allergy product DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said the Aug. 5 PDUFA date...
...scheduled for May 15 to discuss the BLA and may require an additional data submission, DBV...
...HuLuc63, BMS-901608, PDL 063) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Xerava, eravacycline (TP-434, IV TP-434) teplizumab (MGA031, PRV-031) Viaskin Peanut (DBV-712) Novo...
Read More
BioCentury | Feb 21, 2020
Finance

Food allergy company Alladapt raises $60M series C led by Viehbacher's Gurnet Point

...the food allergy therapeutic pipeline," Dombkowski said. Two companies with competing peanut allergy therapies, DBV Technologies S.A. (Euronext:DBV...
...$1 billion around their treatments. Aimmune's Palforzia peanut allergen powder has gained FDA approval, while DBV's...
Read More
BioCentury | Feb 8, 2020
Management Tracks

Gottlieb joins Illumina’s board; plus Kiniksa, Frequency, DBV, VectivBio and more

...Geller as head of intellectual property. She held the same role at Casebia Therapeutics. DBV Technologies S.A. (Euronext:DBV...
...development at Flexion Therapeutics (NASDAQ:FLXN). Hongjiang Li and Elizabeth S. Eaton, Staff Writers Dyne Therapeutics Inc. Imara Inc. Pharvaris B.V. DBV Technologies S.A. Complexa...
Read More
Items per page:
1 - 10 of 146